1795122-12-1
1795122-12-1
Chemical Structure
Urapidil-d4
- CAS No.: 1795122-12-1
- Formula:C20H25D4N5O3
- Molecular Weight:391.50
IUPAC Name: 6-((3-(4-(2-methoxyphenyl)piperazin-1-yl-2,2,6,6-d4)propyl)amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione
InChIKey: ICMGLRUYEQNHPF-AREBVXNXSA-N
SMILES: COC1=C(N2CC([2H])([2H])N(C([2H])([2H])C2)CCCNC(N(C(N3C)=O)C)=CC3=O)C=CC=C1
Biological Activity: Urapidil-d4 is the deuterium labeled Urapidil[1]. Urapidil is an α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Urapidil-d4 | Urapidil-d4 is the deuterium labeled Urapidil. Urapidil is an α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Urapidil (Standard) | ≥98% | Urapidil (Standard) is the analytical standard of Urapidil. This product is intended for research and analytical applications. Urapidil is an α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist that can cross the blood-brain barrier. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Urapidil-d3 | 99.93% | Urapidil-d3 is the deuterium labeled Urapidil. Urapidil is an α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Urapidil | 99.30% | Urapidil is an α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist that can cross the blood-brain barrier. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Bopp C, et al. The effect of urapidil, an alpha-1 adrenoceptor antagonist and a 5-HT1A agonist, on the vascular tone of the porcine coronary and pulmonary arteries, the rat aorta and the human pulmonary artery. Eur J Pharmacol. 2016 May 15;779:53-8. [Content Brief]
